HIGH EFFICACY OF THE COMBINATION CHEMOTHERAPY (CT) OF ORAL VINORELBINE (NVBO) AND CAPECITABINE (X) WITH TRASTUZUMAB (H) IN HER2-POSITIVE METASTATIC BREAST CANCER (MBC): UPDATED ANALYSIS OF THE RESULTS OF AN INTERNATIONAL PHASE II TRIAL

被引：0
|
作者：
Chan, A. [1 ]
Ganju, V. [2 ]
Becquart, D. [3 ]
Conte, P. [4 ]
Gil, M. Gil [5 ]
Petruzelka, L. [6 ]
Bernardo, G. [7 ]
Villanova, G. [8 ]
Tubiana-Mathieu, N. [9 ]
机构：
[1] Mt Hosp, Perth, WA, Australia
[2] Frankston Hosp, Melbourne, Vic, Australia
[3] AZ Middelheim, Med Oncol, Antwerp, Belgium
[4] Univ Modena, Univ Hosp, Dept Onc & Hem, I-41100 Modena, Italy
[5] ICO Hosp Duran & Reynals, Lhospitalet De Llobregat, Spain
[6] Gen Fac Hosp, Prague 2, Czech Republic
[7] Fdn S Maugeri, Pavia, Italy
[8] Pierre Fabre Med, Med Affairs Onclo, Boulogne Billancourt, France
[9] CHU Dupuytren, Limoges, France
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：68 / 68
页数：1
相关论文
共 50 条
  • [41] A Phase II trial of trastuzumab (H) plus capecitabine (X) as first-line treatment in patients (pts) with HER-2-positive metastatic breast cancer (MBC)
    Xu, L.
    Song, S.
    Zhu, J.
    Lu, R.
    Li, L.
    Jiao, S.
    Pan, H.
    Tao, M.
    Su, Y.
    Liu, D.
    EJC SUPPLEMENTS, 2005, 3 (02): : 125 - 125
  • [42] Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
    Saura Manich, C.
    Modi, S.
    Krop, I.
    Park, Y. H.
    Kim, S-B.
    Tamura, K.
    Andre, F.
    Iwata, H.
    Ito, Y.
    Tsurutani, J.
    Sohn, J.
    Lee, C.
    Liu, Y.
    Cathcart, J.
    Singh, J.
    Yamashita, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S485 - S486
  • [43] Phase I/II trial of ruxolitinib in combination with trastuzumab in HER2+metastatic breast cancer (MBC)
    Kalinsky, Kevin
    Lee, Shing
    Tiersten, Amy
    Makower, Della F.
    Cigler, Tessa
    Franks, Lauren
    Mundi, Prabhjot
    Chi, Dow-Chung
    Blumberg, Lauren
    Sender, Naomi
    Galazyn, Magdalena
    Hosi, Kristina
    Goel, Anupama
    Klein, Paula
    Andreopoulou, Eleni
    Sparano, Joseph
    Crew, Katherine D.
    Califano, Andrea
    Silva, Jose
    Hershman, Dawn L.
    CANCER RESEARCH, 2020, 80 (04)
  • [44] Phase II Evaluation of a Novel Capecitabine Schedule in Combination with Lapatinib for Patients with HER2-Positive Metastatic Breast Cancer Refractory to Trastuzumab
    Gajria, D.
    Theodoulou, M.
    Feigin, K.
    Patil, S.
    Geneus, S.
    Drullinsky, P.
    D'Andrea, G.
    Lake, D.
    Norton, L.
    Hudis, C.
    Traina, T. A.
    CANCER RESEARCH, 2009, 69 (24) : 803S - 803S
  • [45] Oral vinorelbine (NVBO) in combination with trastuzumab (HER) in metastatic breast cancer (MBC): Data on efficacy and safety when administered in first- or second-line treatment.
    Illarramendi, J. J.
    Blancas, I.
    Bueso, P.
    Carabantes, F.
    Polo Marques, E.
    Ciruelos Gil, E.
    Corral, M.
    Perez, F. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] Pharmacoeconomic analysis of a combination of capecitabine (X) with docetaxel (D) and trastuzumab (H) first-line in HER2-positive advanced or metastatic breast cancer
    Bonetti, A.
    Santoro, A.
    Cirrincione, A.
    Giuliani, G.
    Bell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer: Updated survival results from the phase II PICTURE trial
    Hu, X.
    Cao, J.
    Teng, Y.
    Li, H.
    Zhang, L.
    Ouyang, Q.
    Xie, W.
    Pan, Y.
    Song, Z.
    Ling, X.
    Wu, X.
    Xu, J.
    Li, L.
    Ren, L.
    Wang, H.
    Zhou, D.
    Luo, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S360 - S361
  • [48] Trastuzumab plus Capecitabine and Docetaxel as First-line Therapy for HER2-positive Metastatic Breast Cancer: Phase II Results
    Michalaki, Vasiliki
    Fotiou, Stylianos
    Gennatas, Spyridon
    Gennatas, Constantine
    ANTICANCER RESEARCH, 2010, 30 (07) : 3051 - 3054
  • [49] Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer
    Farhat, Fadi
    Kattan, Joseph G.
    Ghosn, Marwan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (05) : 1069 - 1077
  • [50] Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer
    Fadi Farhat
    Joseph G. Kattan
    Marwan Ghosn
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 1069 - 1077
12345